FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055958936> ?p ?o ?g. }

• W2055958936 endingPage "153" @default.
• W2055958936 startingPage "152" @default.
• W2055958936 abstract "The recently published guidelines from the British Committee for Standards in Haematology (BCSH) on the measurement of non-coumarin anticoagulants and their effects on tests of haemostasis (Kitchen et al, 2014) provide a welcome steer for clinicians. The guidelines stipulate that, for apixaban, both the prothrombin time (PT) and activated partial thromboplastin time (APTT) are insensitive tests and patients may have normal coagulation times despite therapeutic concentrations. This recommendation is based on studies conducted on plasma samples spiked with apixaban (Barrett et al, 2010; Douxfils et al, 2013; Gouin-Thibault et al, 2014; Harenberg et al, 2014; Lowe et al, 2014). To complement this recommendation, we would like to share our experience from patients receiving apixaban at King's College Hospital. Following the National Institute for Care Excellence's (NICE) approval for the use of apixaban for stroke prevention in the context of non-valvular AF in 2013, we have been prescribing apixaban for selected patients according to the local South London Cardiac and Stroke Network criteria (South London Cardiovascular & Stroke Network, 2012). Where clinically indicated (e.g. extremes of body weight, renal dysfunction or presence of interacting drugs), we measured the activity of the apixaban with the STA-liquid anti-Xa assay® (Diagnostica Stago, Asnières-sur-Seine, France), with appropriate calibrators and controls. We also measured PT with the STA-Neoplastine® CI Plus PT assay (Diagnostic Stago, Asnières-sur-Seine, France). Figure 1 illustrates the PT and corresponding apixaban concentrations for patients, where activity was measured. Our results demonstrate that the PT response for patients prescribed apixaban, is not as impressive as that observed with rivaroxaban previously, using the same reagent (Patel et al, 2013), and endorses the findings of published in-vitro work and the BCSH recommendation. Why is this important? At King's, the current guidelines (http://www.kingsthrombosiscentre.org.uk/index.php/anticoagulation) for the management of bleeding for those patients receiving rivaroxaban recommends a PT screening test, in order to determine whether the presence of rivaroxaban may be contributing to bleeding. Our results suggest using the same strategy for patients prescribed apixaban would not be appropriate. With increasing use of these direct-acting oral anticoagulants, it is apparent that a universal PT screening test, which detects the presence of all the direct-Xa inhibitors, does not currently exist. As such, laboratories will have to consider using an anti-Xa assay to determine the relative anticoagulant effect of apixaban, which will additionally provide a drug concentration. Our results also highlight the potential risks associated with the use of screening tests for patients prescribed different direct Xa inhibitors; having one direct Xa inhibitor prolonging the PT and another not so, could be confusing. During the past year, we have had a few instances in our trust where patients have been admitted to hospital on a direct acting oral agent and have had an International Normalized Ratio or a coagulation screen ordered and inappropriately interpreted; this risk has previously been highlighted (Eby, 2013). We once again endorse the recommendations made by the recent BCSH guidance on monitoring of direct oral anticoagulant therapy (Baglin et al, 2012), which stipulates that laboratories should be aware of the sensitivity of their own assays (PT and others) to each direct-acting oral anticoagulant. With an increasing repertoire of oral direct-acting anticoagulants, each of which have distinct effects on tests of haemostasis, education of non-specialist clinicians on how to interpret the results of coagulation tests is essential. The authors have no relevant conflicts of interest to declare. JPP drew the patient samples. PBC analysed the samples. JC, LNR, RKP, RA and JPP co-wrote the letter." @default.
• W2055958936 created "2016-06-24" @default.
• W2055958936 creator A5001996149 @default.
• W2055958936 creator A5002845586 @default.
• W2055958936 creator A5022954240 @default.
• W2055958936 creator A5033900173 @default.
• W2055958936 creator A5054247918 @default.
• W2055958936 creator A5063739447 @default.
• W2055958936 date "2014-10-14" @default.
• W2055958936 modified "2023-10-05" @default.
• W2055958936 title "Normal prothrombin times in the presence of therapeutic levels of apixaban -<i>in-vivo</i>experience from King's College Hospital" @default.
• W2055958936 cites W1884576739 @default.
• W2055958936 cites W1974535354 @default.
• W2055958936 cites W2010099904 @default.
• W2055958936 cites W2048491733 @default.
• W2055958936 cites W2052346781 @default.
• W2055958936 cites W2073510057 @default.
• W2055958936 cites W2085073510 @default.
• W2055958936 cites W2103196751 @default.
• W2055958936 doi "https://doi.org/10.1111/bjh.13187" @default.
• W2055958936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25312941" @default.
• W2055958936 hasPublicationYear "2014" @default.
• W2055958936 type Work @default.
• W2055958936 sameAs 2055958936 @default.
• W2055958936 citedByCount "9" @default.
• W2055958936 countsByYear W20559589362015 @default.
• W2055958936 countsByYear W20559589362017 @default.
• W2055958936 countsByYear W20559589362018 @default.
• W2055958936 countsByYear W20559589362019 @default.
• W2055958936 countsByYear W20559589362021 @default.
• W2055958936 crossrefType "journal-article" @default.
• W2055958936 hasAuthorship W2055958936A5001996149 @default.
• W2055958936 hasAuthorship W2055958936A5002845586 @default.
• W2055958936 hasAuthorship W2055958936A5022954240 @default.
• W2055958936 hasAuthorship W2055958936A5033900173 @default.
• W2055958936 hasAuthorship W2055958936A5054247918 @default.
• W2055958936 hasAuthorship W2055958936A5063739447 @default.
• W2055958936 hasConcept C126322002 @default.
• W2055958936 hasConcept C127413603 @default.
• W2055958936 hasConcept C151730666 @default.
• W2055958936 hasConcept C2776301958 @default.
• W2055958936 hasConcept C2778261982 @default.
• W2055958936 hasConcept C2778382381 @default.
• W2055958936 hasConcept C2778661090 @default.
• W2055958936 hasConcept C2779161974 @default.
• W2055958936 hasConcept C2779343474 @default.
• W2055958936 hasConcept C2780638905 @default.
• W2055958936 hasConcept C2780645631 @default.
• W2055958936 hasConcept C71924100 @default.
• W2055958936 hasConcept C78519656 @default.
• W2055958936 hasConcept C86803240 @default.
• W2055958936 hasConceptScore W2055958936C126322002 @default.
• W2055958936 hasConceptScore W2055958936C127413603 @default.
• W2055958936 hasConceptScore W2055958936C151730666 @default.
• W2055958936 hasConceptScore W2055958936C2776301958 @default.
• W2055958936 hasConceptScore W2055958936C2778261982 @default.
• W2055958936 hasConceptScore W2055958936C2778382381 @default.
• W2055958936 hasConceptScore W2055958936C2778661090 @default.
• W2055958936 hasConceptScore W2055958936C2779161974 @default.
• W2055958936 hasConceptScore W2055958936C2779343474 @default.
• W2055958936 hasConceptScore W2055958936C2780638905 @default.
• W2055958936 hasConceptScore W2055958936C2780645631 @default.
• W2055958936 hasConceptScore W2055958936C71924100 @default.
• W2055958936 hasConceptScore W2055958936C78519656 @default.
• W2055958936 hasConceptScore W2055958936C86803240 @default.
• W2055958936 hasIssue "1" @default.
• W2055958936 hasLocation W20559589361 @default.
• W2055958936 hasLocation W20559589362 @default.
• W2055958936 hasOpenAccess W2055958936 @default.
• W2055958936 hasPrimaryLocation W20559589361 @default.
• W2055958936 hasRelatedWork W2319027422 @default.
• W2055958936 hasRelatedWork W2511296650 @default.
• W2055958936 hasRelatedWork W2603244127 @default.
• W2055958936 hasRelatedWork W2990341591 @default.
• W2055958936 hasRelatedWork W3109091171 @default.
• W2055958936 hasRelatedWork W3130887320 @default.
• W2055958936 hasRelatedWork W3185663167 @default.
• W2055958936 hasRelatedWork W4210801566 @default.
• W2055958936 hasRelatedWork W4247532592 @default.
• W2055958936 hasRelatedWork W4387036961 @default.
• W2055958936 hasVolume "169" @default.
• W2055958936 isParatext "false" @default.
• W2055958936 isRetracted "false" @default.
• W2055958936 magId "2055958936" @default.
• W2055958936 workType "article" @default.